Breaking News, Collaborations & Alliances

BioAtla & BeiGene Enter Development Pact

Agreement also covers the manufacturing and commercialization of BioAtla’s investigational CAB CTLA-4 antibody (BA3071)

BioAtla and BeiGene, Ltd. have entered into a global co-development and collaboration agreement for the development, manufacturing and commercialization of BioAtla’s investigational CAB CTLA-4 antibody (BA3071).    BA3071 is a novel, CTLA-4 inhibitor that is designed to be conditionally activated in the tumor microenvironment in order to reduce systemic toxicity and potentially enable safer combinations with checkpoint inhibitors such as BeiGene’s investigational anti-PD-1 antibody, tisl...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters